Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xechem International -- Ignore unavailable to you. Want to Upgrade?

To: GatewayStocks who wrote (8)	2/28/2006 9:27:12 PM
From: GatewayStocks	Read Replies (1) \| Respond to of 75

Xechem's Orphan Drug Status Approved for Its Sickle Cell Medicine in the European Union Tuesday October 4, 8:30 am ET NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Oct. 4, 2005--Xechem International, Inc. (OTC BB: XKEM - News) Xechem International announced today that its wholly owned subsidiary, Xechem UK Ltd., has received Orphan Drug designation from the European Medicine Evaluation Agency (EMEA) for NIPRISAN (now known as NICOSAN(TM)/HEMOXIN(TM)), a phytopharmaceutical product that has shown efficacy in the treatment of Sickle Cell Disease. The designation covers all 25 countries that comprise the European Union. Similar Orphan Drug status was previously granted to Xechem by the U.S. Food and Drug Administration. ADVERTISEMENT Dr. Ramesh Pandey, Xechem's Chairman & CEO said, "Obtaining Orphan Drug status for our Sickle Cell Disease product in both the European Union and the United States brings to Xechem substantial advantages and incentives which will help facilitate approval of the drug and make it easier for us to bring this important medicine to market. To have received these coveted designations from both the FDA and EMEA for a natural, herb-based product such as ours is particularly gratifying." Significance of Orphan Drug Designation The EMEA regulation on orphan medicinal products is designed to encourage companies to develop and market treatments for rare, life threatening medical conditions that affect less than five people in every 10,000 in the EU. In addition to granting the license holder protection from direct or generic competition for a period of ten years within the EU following drug approval, orphan drug status allows for regulatory assistance, reduced regulatory fees associated with applying for marketing approval, protocol assistance and scientific advice. Similar incentives, including seven years of marketing exclusivity, tax credits, and access to potential grant funding for non-clinical and clinical research, accompany orphan drug status in the U.S. According to Dr. Pandey, "Given the virtual lack of commercially viable treatments for SCD in the United States and the EU, the multi-year exclusivity for NICOSAN(TM)/HEMOXIN(TM) could create a significant revenue producing opportunity for Xechem." About Sickle Cell Disease Sickle Cell Disease (SCD) is a devastating hereditary blood disorder, caused by an abnormal Hemoglobin called Sickle Hemoglobin, and is characterized by acute painful crises, organ damage, anemia and early death. SCD is particularly prevalent among people from sub-Saharan Africa. In Nigeria alone over 4 million people are afflicted with the disease and another 26 million are believed to be carriers of the sickle cell trait. It is estimated that more than one out of seven persons living on the African continent carry the sickle cell trait and over 18 million actually suffer with the disease worldwide.

To: GatewayStocks who wrote (8)	2/28/2006 9:47:47 PM
From: Chuca Marsh	Read Replies (1) \| Respond to of 75

I have to say ur DD is great. I saw ur other sitee DD at another Gateway Stocks Favorite so I copied it ...u already poosted it here ...I had no idea how international this co I invested heavily in is at in Xechem Locations Corporate Headquarters Xechem International, Inc. New Brunswick Technology Center 100 Jersey Avenue Building B, Suite 310 New Brunswick, NJ 08901 USA INSERT NEW INFO ON EDIT addressses continue lower:: "" SUBJECT: XKEM won lawsuit against Giant Drug manufactu Posted By: thewallmaster Post Time: 2/26/2006 20:23 « Previous Message Next Message » XKEM won lawsuit against Giant Drug manufacture Brystol Myers. XKEM,has a knockoff cancer drug coming to market soon, also has a Sickel Cell drug out this quarter.Just won a law suit against Brystol Myers, which in itself is impressive for a penny stock company to win against one of the giant drug manufacturers. This stock should have news out this week or next week regarding the Sickell Cell drug coming to market. I like the potential of XKEM. finance.yahoo.com quote from a Raging Bull poster: Posted by: dawg245 In reply to: thewallmaster who wrote msg# 319 Date:2/24/2006 5:12:35 PM Post #of 331 What impresses me is that XKEM went head to head with Bristol-Myers........and won. Now, if the sickle cell drug expands from Nigeria to the rest of the world we will all be rich, very rich. TAKE THAT NAKED SHORTERS ----------------------------------------------- XKEM buy alert The SouthEnd Stock Pickers helps investors win at investing on the merits of radically original thinking and an unbeatable track record of picking stocks with huge potential. We're here for you with commonsense, the big ideas, and a little inspiration to turn your portfolio into a monster performer. We've brought you GTE, GOOG, SIRI, CMGI, JDSU,HISC, and others you've made a killing on! If it doesn't make commonsense, it makes nosense to us or you. At SouthEnd Stock Pickers, we're focusing solely on undervalued Nasdaq stocks that we feel will return potential profits of 500%+ in 1 to 3 weeks. Our New picks have hours and hours of research listed below.Our SouthEnd Team uses a new breakthrough method of hardcore stock picks.$$ WE ARE HERE TO MAKE YOU MONEY $$ Our new pick for 22/FEB/2006 is XKEM) was picked up of (INSIDER BUYING) Accumulation........is the key word Xechem International,Inc, Ticker Symbol = XKEM Market Cap = $ 1. 90M Industry: Biotechnology Target Price = $ 0.24 Recommendation: SUPER MEGA BUY There are many reasons to buy into (XKEM) $DO YOUR DD A HUGE WINNER HERE $ Once News on the Approval of the NIGERIA plant comes out SKY HIGH SHE GOES . Charts speak for them selfs RSI strong buy freewebs.com stockcharts.com Web Site: xechem.com stockhouse.ca; "" stockhouse.ca end of INSERT (Xechem, Inc., Xechem Laboratories, Inc., and XetaPharm, Inc. are also located at the above address) Tel: (732) 247-3300 Fax: (732) 247-4090 E-Mail: xechem@erols.com Regional Office Xechem/XetaPharm, Inc. 12106 Pawnee Drive Gaithersburg, MD 20878 USA Tel: (301) 330-5098 Fax: (301) 330 5098 E-Mail: xechem-reg@hotmail.com Xechem Nigeria Xechem Pharmaceuticals Nigeria Ltd. Sheda Science and Technology Complex Technology Park, Gwagwalada Federal Capital Territory, Abuja NIGERIA Tel: 234-9-671-8379 E-Mail: xechemnigeria@yahoo.com Xechem U.K. Xechem U.K., Ltd. The White House 2 Meadrow Godalming Surrey GU7 3HN UK Tel: 44 (0) 1483 424 269 Fax: 44 (0) 1483 424 310 Xechem India Xechem (India) Pvt. Ltd. B-3/17, Safdarjung Enclave New Delhi 110029 INDIA Tel: 011-91-11-2-618-4293 Tel: 011-91-11-2-618-4294 Fax: 011-91-11-2-618-4295 Email: xechem@bol.net.in Credit To Old Gateway - Mooooooooooooooooooo! I guess ur not a computer LOL or are u?